Alex­ion looks to set­tle law­suit over Soliris sales prac­tices for $125M

A 2016 class ac­tion law­suit filed against Alex­ion claim­ing shady sales prac­tices caused a de­cline in stock price could be near­ing its end af­ter both sides have asked a fed­er­al judge to ap­prove a $125 mil­lion set­tle­ment.

In the set­tle­ment, Alex­ion will not have to ad­mit wrong­do­ing, ac­cord­ing to court doc­u­ments filed Wednes­day.

The class ac­tion law­suit be­gan on be­half of stock­hold­ers who pur­chased stock be­tween Jan. 30, 2014 and May 26, 2017, al­leg­ing that Alex­ion and some of its ex­ec­u­tives used il­le­gal tac­tics to in­crease sales of its drug Soliris, which costs around $440,00 a year, ac­cord­ing to the law­suit — mak­ing it one of the world’s most ex­pen­sive drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER